European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

• The European Patent Office (EPO) has granted WEHI a patent for CISH knockout (KO) in Natural Killer (NK) cells which is exclusively licensed to ONK Therapeutics for cell immunotherapy purposes, giving ONK key IP for CISH KO in human NK cells for use in cancer therapies, irrespective of cell origin
• The CISH IP forms part of ONK’s broad and growing IP estate covering the optimization of persistence, metabolic profile and cytotoxic potential of its NK cell therapy platform

Galway, Ireland and San Diego, USA, 27 June 2023 - ONK Therapeutics Ltd, an innovative NK cell therapy company, today announced that the European Patent Office (EPO) has granted its licensed patent covering CISH knockout (KO) in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells (iPSCs).

The patent granted to ONK’s licensor, WEHI (Walter and Eliza Hall Institute of Medical Research), by the EPO is part of a portfolio which includes granted US, Australian, New Zealand and Japanese patents as well as pending applications in several other countries.

ONK licensed the patent family relating to the KO of CISH in NK cells in an exclusive global patent license agreement from WEHI in 2021. CISH KO has been shown to improve the persistence, metabolic profile, and cytotoxicity of NK cells. The patent granted by EPO specifically covers CISH KO NK cells per se, and cancer therapies that utilize NK cells with CISH KO as well as NK cells engineered with the foundational CISH KO in combination with IL-15 (soluble or engineered), TGFβR2 KO, or TGFβR2 KO and IL-15 (soluble or engineered).

ONK and WEHI continue to prosecute the CISH patent portfolio in a way to maximize its depth and breadth of scope. It forms part of ONK’s broad and growing IP estate covering the optimization of persistence, metabolic profile and cytotoxic potential of its NK cell therapy platform.

ONK Therapeutics’ CEO Chris Nowers said, “Editing of NK cells to knockout CISH has the potential to improve the potency and persistence of NK cell-based therapies and provide greater benefit to patients. We are actively exploring the merits of CISH KO alone or in combination with other gene edits such as TGFβR2 KO and IL-15 knock-in. We believe this is the foundational CISH KO patent, based on the earliest scientific discoveries and covers CISH KO NK cells from any source. We are excited to have this broad and evolving patent estate which underpins our scientific efforts in the field.”

WEHI’s Head of Biotechnology and Commercialisation Dr Anne-Laure Puaux said, “Cell-based therapies have demonstrated their enormous potential as disease-modifying therapies in oncology.  Partnerships and collaborations are key to advancing WEHI’s drug discovery and development programs, to help us take our research from the lab to the clinic. Through this license agreement with ONK Therapeutics, we are excited to support the opportunity to develop more potent cell-based therapies for the future benefit of cancer patients.”